[EN] DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS [FR] ANTAGONISTES DU RÉCEPTEUR DE L'ENDOTHÉLINE ET DE L'ANGIOTENSINE À DOUBLE ACTION
摘要:
The present disclosure relates generally to dual-acting angiotensin and endothelin receptor antagonists, or pharmaceutically acceptable salts, isotopically enriched analogs, stereoisomers, mixtures of stereoisomers, or prodrugs thereof, and methods of making and using the same.
Dihydropyrimidine angiotensin II receptor antagonists
作者:Karnail S. Atwal、Syed Z. Ahmed、J. Eileen Bird、Carol L. Delaney、Kenneth E. J. Dickinson、Francis N. Ferrara、Anders Hedberg、Arthur V. Miller、Suzanne Moreland
DOI:10.1021/jm00103a014
日期:1992.12
publication. Structure-activitystudies showed that a variety of substituents are tolerated on the dihydropyrimidine ring, indicating that the AII receptor is permissive in accepting this region of the nonpeptide antagonists. As reported for imidazole-based AII antagonists, the tetrazolyl dihydropyrimidine analogs were found to be more potent than the corresponding carboxylic acids. Our studies show that
[EN] DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR DE L'ENDOTHÉLINE ET DE L'ANGIOTENSINE À DOUBLE ACTION
申请人:[en]ARIA PHARMACEUTICALS, INC.
公开号:WO2023224963A1
公开(公告)日:2023-11-23
The present disclosure relates generally to dual-acting angiotensin and endothelin receptor antagonists, or pharmaceutically acceptable salts, isotopically enriched analogs, stereoisomers, mixtures of stereoisomers, or prodrugs thereof, and methods of making and using the same.